Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Cerdulatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1198300-79-6, Cerdulatinib (prt062070), Prt062070, Cerdulatinib [inn], 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide, Prt-062070
    Molecular Formula
    C20H27N7O3S
    Molecular Weight
    445.5  g/mol
    InChI Key
    BGLPECHZZQDNCD-UHFFFAOYSA-N
    FDA UNII
    D1LXQ45S1O
    Cerdulatinib is an orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon oral administration, cerdulatinib specifically binds to and inhibits the activity of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated signaling and functional responses. This negatively affects the downstream JAK-STAT (signal transducer and activator of transcription) pathway, and leads to both reduced inflammation in various animal models and enhanced antiproliferative activity towards non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine kinase involved in signal transduction in cells of hematopoietic origin including B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been implicated in several hematopoietic malignancies including NHL and chronic lymphocytic leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide
    2.1.2 InChI
    InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
    2.1.3 InChI Key
    BGLPECHZZQDNCD-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
    2.2 Other Identifiers
    2.2.1 UNII
    D1LXQ45S1O
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

    2. Prt062070

    2.3.2 Depositor-Supplied Synonyms

    1. 1198300-79-6

    2. Cerdulatinib (prt062070)

    3. Prt062070

    4. Cerdulatinib [inn]

    5. 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide

    6. Prt-062070

    7. D1lxq45s1o

    8. Chembl4116008

    9. Rvt-502

    10. Prt-2070

    11. Prt 062070

    12. 4-(cyclopropylamino)-2-((4-(4-(ethanesulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

    13. 5-pyrimidinecarboxamide, 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)-1-piperazinyl)phenyl)amino)-

    14. Prt2070

    15. Unii-d1lxq45s1o

    16. 4-(cyclopropylamino)-2-({4-[4-(ethanesulfonyl)piperazin-1-yl]phenyl}amino)pyrimidine-5-carboxamide

    17. Cerdulatinib (prt2070)

    18. Cerdulatinib [who-dd]

    19. Schembl736734

    20. Gtpl8957

    21. Dtxsid001115521

    22. Bcp10681

    23. Ex-a2143

    24. Yxb30079

    25. Bdbm50468574

    26. Nsc800071

    27. Nsc825827

    28. S3566

    29. Akos026750510

    30. Zinc114483165

    31. Cs-3329

    32. Db15499

    33. Nsc-800071

    34. Nsc-825827

    35. Sb16931

    36. Cerdulatinib; Prt062070; Prt2070

    37. Ncgc00386415-04

    38. 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide

    39. Ac-30243

    40. As-56368

    41. Da-34986

    42. Hy-15999

    43. B8023

    44. Ft-0741914

    45. A14147

    46. C71670

    47. Q27075860

    48. Prt2070; Prt-2070; Prt 2070; Prt-062070; Prt 062070; Prt062070

    49. 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide

    2.4 Create Date
    2010-02-01
    3 Chemical and Physical Properties
    Molecular Weight 445.5 g/mol
    Molecular Formula C20H27N7O3S
    XLogP31.9
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count8
    Exact Mass445.18960892 g/mol
    Monoisotopic Mass445.18960892 g/mol
    Topological Polar Surface Area142 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity711
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.